First Participant Vaccinated In Bundibugyo Vaccine Trial In DRC
A clinical trial named 'Tumaini' has begun in the Democratic Republic of the Congo to test vaccines against the Bundibugyo virus. The trial uses an adaptive platform to evaluate multiple candidates, including Ervebo, in response to a major outbreak.
Why it matters
The trial is critical for public health, as there are currently no approved vaccines for the Bundibugyo virus, which has caused thousands of deaths in the region.
The first participant has been vaccinated in a pivotal clinical trial to evaluate vaccine candidates against Bundibugyo virus in the Democratic Republic of the Congo (DRC).
The Coalition for Epidemic Preparedness Innovations (CEPI) disclosed this in a statement obtained by the News Agency of Nigeria (NAN) from its website on Friday.
The trial, named Tumaini, meaning “hope” in Swahili, will evaluate the safety, immunogenicity and efficacy of candidates, including Ervebo, against the virus.
The statement said the first vaccination was administered on Friday in Bunia, DRC, marking the start of the Phase 2/3 trial supporting the government-led outbreak response.
It said the trial began as the country faced the largest recorded Bundibugyo virus outbreak and the second-largest Ebola outbreak yet.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in